SCHEMBL2118752

SCHEMBL2118752

Cc1c(C(=O)O)c(C)n(C(C(N)=O)N(C)C)c1C=C1C(=O)Nc2cc(-c3ccccc3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 12/20 0.46
▸ PDGFRB P09619 10/20 0.46
▸ FGFR1 P11362 8/20 0.46
▸ EGFR P00533 5/20 0.46
▸ CHEK1 O14757 5/20 0.42
▸ FLT4 P35916 3/20 0.42
▸ FLT3 P36888 3/20 0.42
▸ KIT P10721 2/20 0.42
▸ CDK2 P24941 1/20 0.39
▸ AURKB Q96GD4 2/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ RET P07949 1/20 0.39
▸ MET P08581 1/20 0.39
▸ PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2116213 0.91 FGFR1 (0.51) KDRPDGFRBFGFR1EGFRCHEK1
SCHEMBL2114117 0.91 KDR (0.46) KDRPDGFRBFGFR1EGFRCHEK1
SCHEMBL394231 0.85 FLT3 (0.50) KDRPDGFRBFLT4FLT3KIT
SCHEMBL2115512 0.84 KDR (0.49) KDRPDGFRBFGFR1EGFRCHEK1
SCHEMBL2114212 0.84 KDR (0.44) KDRPDGFRBFGFR1EGFRCHEK1
SCHEMBL2114116 0.84 LRRK2 (0.42) KDRPDGFRBFGFR1EGFRFLT4
SCHEMBL2114389 0.82 FLT3 (0.41) KDRPDGFRBFGFR1EGFRCHEK1
SCHEMBL2113982 0.82 KDR (0.47) KDRPDGFRBFGFR1EGFRCHEK1
SCHEMBL2113945 0.82 LRRK2 (0.45) KDRPDGFRBFGFR1EGFRFLT4
SCHEMBL2115891 0.82 MEN1 (0.48) KDRPDGFRBFGFR1EGFRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2012-04-19 — — US disclosed
EP-1536783-B1 SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND PFIZER ITALIA SRL (IT) 2008-08-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates PTK2B, ERBB2, FRK KDR 395/4885PDGFRB 555/4885FGFR1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback